171 related articles for article (PubMed ID: 21449727)
1. Increased expression of CD69 on T cells as an early immune marker for human cytomegalovirus reactivation in chronic lymphocytic leukemia patients.
Petersen CC; Nederby L; Roug AS; Skovbo A; Peterslund NA; Hokland P; Nielsen B; Hokland M
Viral Immunol; 2011 Apr; 24(2):165-9. PubMed ID: 21449727
[TBL] [Abstract][Full Text] [Related]
2. Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir.
Laurenti L; Piccioni P; Cattani P; Cingolani A; Efremov D; Chiusolo P; Tarnani M; Fadda G; Sica S; Leone G
Haematologica; 2004 Oct; 89(10):1248-52. PubMed ID: 15477211
[TBL] [Abstract][Full Text] [Related]
3. Cord blood graft composition impacts the clinical outcome of allogeneic stem cell transplantation.
Wikell H; Ponandai-Srinivasan S; Mattsson J; Gertow J; Uhlin M
Transpl Infect Dis; 2014 Apr; 16(2):203-12. PubMed ID: 24456214
[TBL] [Abstract][Full Text] [Related]
4. Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia.
Lundin J; Porwit-MacDonald A; Rossmann ED; Karlsson C; Edman P; Rezvany MR; Kimby E; Osterborg A; Mellstedt H
Leukemia; 2004 Mar; 18(3):484-90. PubMed ID: 14749699
[TBL] [Abstract][Full Text] [Related]
5. Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab.
O'Brien SM; Keating MJ; Mocarski ES
Clin Lymphoma Myeloma; 2006 Sep; 7(2):125-30. PubMed ID: 17026823
[TBL] [Abstract][Full Text] [Related]
6. HCMV infection of PDCs deviates the NK cell response into cytokine-producing cells unable to perform cytotoxicity.
Cederarv M; Söderberg-Nauclér C; Odeberg J
Immunobiology; 2009; 214(5):331-41. PubMed ID: 19152985
[TBL] [Abstract][Full Text] [Related]
7. The CD94/NKG2C-expressing NK cell subset is augmented in chronic lymphocytic leukemia patients with positive human cytomegalovirus serostatus.
Petersen L; Roug AS; Skovbo A; Thysen AH; Eskelund CW; Hokland ME
Viral Immunol; 2009 Oct; 22(5):333-7. PubMed ID: 19811091
[TBL] [Abstract][Full Text] [Related]
8. Late Development of FcεRγ
Muccio L; Falco M; Bertaina A; Locatelli F; Frassoni F; Sivori S; Moretta L; Moretta A; Della Chiesa M
Front Immunol; 2018; 9():1050. PubMed ID: 29868012
[TBL] [Abstract][Full Text] [Related]
9. Human cytomegalovirus particles directly suppress CD4 T-lymphocyte activation and proliferation.
Fornara O; Odeberg J; Khan Z; Stragliotto G; Peredo I; Butler L; Söderberg-Nauclér C
Immunobiology; 2013 Aug; 218(8):1034-40. PubMed ID: 23434301
[TBL] [Abstract][Full Text] [Related]
10. Elevated granzyme M-expressing lymphocytes during cytomegalovirus latency and reactivation after allogeneic stem cell transplantation.
Bovenschen N; Spijkers SN; Wensink AC; Schellens IM; van Domselaar R; van Baarle D
Clin Immunol; 2014 Jan; 150(1):1-11. PubMed ID: 24316590
[TBL] [Abstract][Full Text] [Related]
11. Signatures of T and B Cell Development, Functional Responses and PD-1 Upregulation After HCMV Latent Infections and Reactivations in Nod.Rag.Gamma Mice Humanized With Cord Blood CD34
Theobald SJ; Khailaie S; Meyer-Hermann M; Volk V; Olbrich H; Danisch S; Gerasch L; Schneider A; Sinzger C; Schaudien D; Lienenklaus S; Riese P; Guzman CA; Figueiredo C; von Kaisenberg C; Spineli LM; Glaesener S; Meyer-Bahlburg A; Ganser A; Schmitt M; Mach M; Messerle M; Stripecke R
Front Immunol; 2018; 9():2734. PubMed ID: 30524448
[TBL] [Abstract][Full Text] [Related]
12. Cytomegalovirus-specific CD4 T-cell and glycoprotein B specific antibody response in recipients of allogenic stem cell transplantation.
Ludwig B; Kraus FB; Kipp M; Preiser W; Schwerdtfeger R; Doerr HW; Buxbaum S
J Clin Virol; 2006 Feb; 35(2):160-6. PubMed ID: 16112610
[TBL] [Abstract][Full Text] [Related]
13. Association of atherosclerosis with expression of the LILRB1 receptor by human NK and T-cells supports the infectious burden hypothesis.
Romo N; Fitó M; Gumá M; Sala J; García C; Ramos R; Muntasell A; Masiá R; Bruguera J; Subirana I; Vila J; de Groot E; Elosua R; Marrugat J; López-Botet M
Arterioscler Thromb Vasc Biol; 2011 Oct; 31(10):2314-21. PubMed ID: 21817101
[TBL] [Abstract][Full Text] [Related]
14. Decreased expression of CD69 in chronic fatigue syndrome in relation to inflammatory markers: evidence for a severe disorder in the early activation of T lymphocytes and natural killer cells.
Mihaylova I; DeRuyter M; Rummens JL; Bosmans E; Maes M
Neuro Endocrinol Lett; 2007 Aug; 28(4):477-83. PubMed ID: 17693977
[TBL] [Abstract][Full Text] [Related]
15. Detection of human cytomegalovirus-specific T lymphocytes in human blood: comparison of two methods.
Schermann CM; Fischer G; Witt V; Kurz M; Potschger U; Fritsch G
Cytotherapy; 2008; 10(8):834-41. PubMed ID: 19016371
[TBL] [Abstract][Full Text] [Related]
16. Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy.
O'Brien S; Ravandi F; Riehl T; Wierda W; Huang X; Tarrand J; O'Neal B; Kantarjian H; Keating M
Blood; 2008 Feb; 111(4):1816-9. PubMed ID: 18039954
[TBL] [Abstract][Full Text] [Related]
17. Severe Symptomatic Primary Human Cytomegalovirus Infection despite Effective Innate and Adaptive Immune Responses.
Riou R; Bressollette-Bodin C; Boutoille D; Gagne K; Rodallec A; Lefebvre M; Raffi F; Senitzer D; Imbert-Marcille BM; Retière C
J Virol; 2017 Mar; 91(5):. PubMed ID: 28031361
[TBL] [Abstract][Full Text] [Related]
18. Intense antiextracellular adaptive immune response to human cytomegalovirus in very old subjects with impaired health and cognitive and functional status.
Vescovini R; Biasini C; Telera AR; Basaglia M; Stella A; Magalini F; Bucci L; Monti D; Lazzarotto T; Dal Monte P; Pedrazzoni M; Medici MC; Chezzi C; Franceschi C; Fagnoni FF; Sansoni P
J Immunol; 2010 Mar; 184(6):3242-9. PubMed ID: 20173031
[TBL] [Abstract][Full Text] [Related]
19. Molecular characterization of HCMV-specific immune responses: Parallels between CD8(+) T cells, CD4(+) T cells, and NK cells.
Vieira Braga FA; Hertoghs KM; van Lier RA; van Gisbergen KP
Eur J Immunol; 2015 Sep; 45(9):2433-45. PubMed ID: 26228786
[TBL] [Abstract][Full Text] [Related]
20. Expansion of the NKG2C+ natural killer-cell subset is associated with high-risk carotid atherosclerotic plaques in seropositive patients for human cytomegalovirus.
Martínez-Rodríguez JE; Munné-Collado J; Rasal R; Cuadrado E; Roig L; Ois A; Muntasell A; Baro T; Alameda F; Roquer J; López-Botet M
Arterioscler Thromb Vasc Biol; 2013 Nov; 33(11):2653-9. PubMed ID: 23968979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
